
|Articles|July 1, 2001
Molecular assays may aid bladder cancer control
Washington-An evolution in the management of bladder cancer, including the use of molecular-based diagnostic testing, may soon make it possible to achieve better outcomes at a lower cost, according to Mark P. Schoenberg, MD. Dr. Schoenberg, associate professor of urology and oncology and director of the bladder cancer research center at the Johns Hopkins School of Medicine in Baltimore, said that a change in some aspects of bladder cancer management is sorely needed.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
3
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
4
Study suggests potential diuretic effect with nadofaragene firadenovec
5











